Invitrogen Introduces Next Generation of Transfection Reagents
Complete the form below to unlock access to ALL audio articles.
Invitrogen Corporation has introduced a key product into its line of transfection reagents.
Lipofectamine™ LTX is designed to provide effective delivery of DNA into a wide range of cell types and a significantly lower toxicity profile.
Lipofectamine™ LTX Reagent delivers DNA into the cell and demonstrates high levels of transfection efficiency and protein expression with 90 percent viability for a wide range of cells, including primary neuronal cells and other disease-relevant cell types.
Understanding gene function, in turn, helps researchers learn about the molecular basis of disease formation and develop potential therapeutic strategies to combat disease.
The introduction of Lipofectamine™ LTX complements Invitrogen's release earlier this year of another member of the Lipofectamine™ product line.
Lipofectamine™ RNAi MAX is a RNAi-specific transfection reagent that is designed to offer high transfection efficiency and low toxicity profiles on a wide variety of cell types for siRNA gene knockdown experiments.
"These technologies add significant capabilities to a transfection portfolio that is already widely adopted throughout the industry and was instrumental in establishing applications such as RNAi and stem cell research," said Claude Benchimol, Ph.D., Senior Vice President of Research and Development for Invitrogen.
"Our commitment to continual improvement in our core technologies is demonstrated in the release of Lipofectamine™ LTX and Lipofectamine™ RNAi MAX," concluded Mark Gardner, Invitrogen's Vice President of Molecular Biology Essentials.
"Lipofectamine™ 2000 is one of our company's top products, and with the advances these new reagents provide, we have a chance to support new and rapidly expanding research applications with the next generation of gene delivery solutions."